87 related articles for article (PubMed ID: 19874807)
1. Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats.
Borbath I; Leclercq IA; Sempoux C; Abarca-Quinones J; Desaeger C; Horsmans Y
Chem Biol Interact; 2010 Jan; 183(1):238-48. PubMed ID: 19874807
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide.
Borbath I; Leclercq IA; Abarca-Quinones J; Desaeger C; Lebrun V; Moulin P; Sempoux C; Horsmans Y
Cancer Sci; 2007 Dec; 98(12):1831-9. PubMed ID: 17900309
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models.
Borbath I; Stärkel P
Acta Gastroenterol Belg; 2011 Mar; 74(1):34-44. PubMed ID: 21563652
[TBL] [Abstract][Full Text] [Related]
4. Effects of a long-acting somatostatin analogue, lanreotide, on bile duct ligation-induced liver fibrosis in rats.
Tahan G; Eren F; Tarçin O; Akin H; Tahan V; Şahın H; Özdoğan O; İmeryüz N; Çelıkel Ç; Avşar E; Tözün N
Turk J Gastroenterol; 2010 Sep; 21(3):287-92. PubMed ID: 20931434
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide.
Raderer M; Hejna MH; Kurtaran A; Kornek GV; Valencak JB; Oberhuber G; Vorbeck F; Virgolini I; Scheithauer W
Am J Gastroenterol; 1999 Jan; 94(1):278-9. PubMed ID: 9934776
[TBL] [Abstract][Full Text] [Related]
6. The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver.
Borbath I; Leclercq I; Moulin P; Sempoux C; Horsmans Y
Eur J Cancer; 2007 Jul; 43(11):1755-63. PubMed ID: 17582756
[TBL] [Abstract][Full Text] [Related]
7. Lanreotide treatment of metastatic hepatocellular carcinoma resulting in partial regression and more than 3 years of progression-free survival.
Borbath I; Lhommel R; Guiot Y; Coche E; Sempoux C
Acta Gastroenterol Belg; 2012 Jun; 75(2):270-3. PubMed ID: 22870795
[TBL] [Abstract][Full Text] [Related]
8. Regulation of PKB/Akt-pathway in the chemopreventive effect of lactoferrin against diethylnitrosamine-induced hepatocarcinogenesis in rats.
Hegazy RR; Mansour DF; Salama AA; Abdel-Rahman RF; Hassan AM
Pharmacol Rep; 2019 Oct; 71(5):879-891. PubMed ID: 31442665
[TBL] [Abstract][Full Text] [Related]
9. Slow-release lanreotide treatment in endocrine gastrointestinal tumors.
Tomassetti P; Migliori M; Gullo L
Am J Gastroenterol; 1998 Sep; 93(9):1468-71. PubMed ID: 9732927
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of Diethylnitrosamine-Initiated and Phenobarbital-Promoted Hepatocarcinogenesis in Rats by Sulfated Polysaccharides and Aqueous Extract of Ulva lactuca.
Hussein UK; Mahmoud HM; Farrag AG; Bishayee A
Integr Cancer Ther; 2015 Nov; 14(6):525-45. PubMed ID: 26130745
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results.
Raderer M; Hamilton G; Kurtaran A; Valencak J; Haberl I; Hoffmann O; Kornek GV; Vorbeck F; Hejna MH; Virgolini I; Scheithauer W
Br J Cancer; 1999 Feb; 79(3-4):535-7. PubMed ID: 10027326
[TBL] [Abstract][Full Text] [Related]
12. High-saturate-fat diet delays initiation of diethylnitrosamine-induced hepatocellular carcinoma.
Duan XY; Pan Q; Yan SY; Ding WJ; Fan JG; Qiao L
BMC Gastroenterol; 2014 Nov; 14():195. PubMed ID: 25410681
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo.
Raderer M; Hejna MH; Muller C; Kornek GV; Kurtaran A; Virgolini I; Fiebieger W; Hamilton G; Scheithauer W
Int J Oncol; 2000 Jun; 16(6):1197-201. PubMed ID: 10811995
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats.
Molina-Trinidad EM; de Murphy CA; Jung-Cook H; Stack EM; Pedraza-Lopez M; Morales-Marquez JL; Serrano GV
J Pharm Pharmacol; 2010 Apr; 62(4):456-61. PubMed ID: 20604834
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis.
Bishayee A; Dhir N
Chem Biol Interact; 2009 May; 179(2-3):131-44. PubMed ID: 19073162
[TBL] [Abstract][Full Text] [Related]
16. INHIBITORY EFFECT OF TETRAMETHYLPYRAZINE ON HEPATOCELLULAR CARCINOMA: POSSIBLE ROLE OF APOPTOSIS AND CELL CYCLE ARREST.
Cao J; Miao Q; Zhang J; Miao S; Bi L; Zhang S; Yang Q; Zhou X; Zhang M; Xie Y; Wang S
J Biol Regul Homeost Agents; 2015; 29(2):297-306. PubMed ID: 26122217
[TBL] [Abstract][Full Text] [Related]
17. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations.
Abdel-Rahman O; Lamarca A; Valle JW; Hubner RA
Endocr Relat Cancer; 2014; 21(6):R485-93. PubMed ID: 25336571
[TBL] [Abstract][Full Text] [Related]
19. Different lineages of chemically induced hepatocellular carcinoma in rats defined by monoclonal antibodies.
Dunsford HA; Karnasuta C; Hunt JM; Sell S
Cancer Res; 1989 Sep; 49(17):4894-900. PubMed ID: 2474377
[TBL] [Abstract][Full Text] [Related]
20. A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma.
Di Leo A; Bajetta E; Ferrari L; Biganzoli L; Mariani L; Carnaghi C; Camerini E; Buzzoni R; Ruiz JM
Cancer; 1996 Jul; 78(1):35-42. PubMed ID: 8646723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
